{
    "id": 27154,
    "fullName": "CD38 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD38 positive indicates the presence of the CD38 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 952,
        "geneSymbol": "CD38",
        "terms": [
            "CD38",
            "ADPRC 1",
            "ADPRC1"
        ]
    },
    "variant": "positive",
    "createDate": "10/24/2017",
    "updateDate": "01/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOR202 treatment induced cytotoxicity against CD38-positive multiple myeloma cell lines when co-cultured with macrophages in culture (PMID: 29654274).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9050,
                "therapyName": "MOR202",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17089,
                    "pubMedId": 29654274,
                    "title": "Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29654274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19455,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOR202 treatment supplemented with vitamin D resulted in enhanced cytotoxicity against CD38-positive multiple myeloma cell lines co-cultured with Revlimid (lenalidomide)-treated patient-derived monocytes or macrophages in culture (PMID: 29654274).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9053,
                "therapyName": "Lenalidomide + MOR202 + Vitamin D",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17089,
                    "pubMedId": 29654274,
                    "title": "Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29654274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20821,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-169 treatment induced cytotoxicity against multiple myeloma cell lines expressing CD38 in culture, and induced regression in a cell line xenograft model and killing of patient cells, including Darzalex (Daratumumab)-resistant cells, in culture (Cancer Res 2019;79(13 Suppl):Abstract nr 2384).",
            "molecularProfile": {
                "id": 28560,
                "profileName": "CD38 positive"
            },
            "therapy": {
                "id": 9488,
                "therapyName": "TAK-169",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18081,
                    "pubMedId": null,
                    "title": "TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28560,
            "profileName": "CD38 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}